雷递网 雷建平 12月15日 轻松健康集团（股票代码："2661"）今日开启招股，准备2025年12月23日在港交所上市。 轻松健康拟全球发售2654万股，最高发售价22.68港元，预计募资总额为6亿港元，扣除发行应付上市费 用，募资净额5.13亿港元。 | | | | 假設超额配股權 | | 假設超额配股權 | | | --- | --- | --- | --- | --- | --- | --- | | | | | 尚未行使 | | 獲悉數行使 | | | | | | | 估紧隙 | | 估紧圆 | | | | | | 全球發售 | | 全球發售 | | | | | | 元成後 | | 元成後 | | | | 將予 | | 已發行 | | 已發行 | | 總投资 | | 認購的 | 估發售 | 股本總額 | 佔發售 | 股本塑额 | | 基石投资者 | 金额(1) | 發售股份 | 股份概约 | 概 约 | 股份概约 | 概 釣 | | 名稱 | (百萬元) | 题目(3) | 百分比 | 百分比 | 百分比 | 百分比 | | 按發售價22.68港元計算 | | | | | | | | 澳琴合鸣 | 人 ...

| 全球發售項下的發售股份總數 | : | 26,540,000股股份(視乎超額配股權行使與否而定) | | --- | --- | --- | | 香港發售股份數目 | .. | 2.654.000股股份(可于重新分配) | | 國際發售股份數目 | " | 23,886,000股股份(可予重新分配及視乎 | | | | 超額配股權行使與否而定) | | 發售價 | .. | 每股股份22.68港元,另加1.0%經紀佣金、 | | | | 0.0027%證監會交易徵費、0.00565%聯交所 | | | | 交易費及0.00015%會財局交易徵費(須於 | | | | 申請時以港元繳足,多繳款項可予退還) | | 面值 | : | 每股股份0.0001美元 | | 股份代號 | ። 2661 | | 来自北京的 轻松健康(02661.HK)，于今日(12月15日)起至周四(12月18日)招股，预计2025年12月23日在港交所挂牌上市， 中金公司、 招商证券国际联席 保荐。 招股书显示，轻松健康在上市后的股东架构中，杨胤女士，通过间接持股、以及若干投票代理安排，控制QSC ESO、 WIND ENTERPR ...

公司是中国领先的科技型一站式平台，专注于提供综合健康服务及健康保险解决方案。 公司2023年度、2024年度、2025年半年度截至6月30日止，净利润分别为7364.50万元、1039.80万元、 8604.50万元，同比变动幅度为3673.27%、-85.88%、437.92%。 公司引入广东横琴粤澳深度合作区澳琴合鸣投资合伙企业（有限合伙）等基石投资者，将以发售价共认 购数量下限约480.18万股可购买发售的股份。 轻松健康预计于2025年12月23日在主板上市，中国国际金融香港证券有限公司、招商证券（香港）有限 公司为联席保荐人。 轻松健康(02661.HK)发布公告，公司拟全球发售2654.00万股股份，其中香港发售股份265.40万股，国际 发售股份2388.60万股，另有398.10万股超额配股权。招股日期为12月15日至12月18日，最高发售价 22.68港元，每手买卖单位200股，入场费约4581.75港元。 全球发售预计募资总额为6.02亿港元，募资净额5.13亿港元，募资用途为用于提升公司的品牌知名度、 提高用户参与度及加强与业务合作伙伴的合作；用于提升公司在AI及大数据领域的技术能力，以 ...

轻松健康(2661.HK)今日起至12月18日招股，每股招股价22.68港元，发售2654万股，香港公开发售占 10%，其余为国际配售，集资最多6.01亿港元。一手200股，入场费4581.75港元。该股预期12月23日挂 牌。 轻松健康是中国的一站式平台，专注于提供数字综合健康服务及健康保险解决方案。此次IPO该公 司拟将所得款项净额约40%用于提升品牌知名度、提高用户参与度及加强与业务合作伙伴的合作；约 20%用于医学研究和真实世界研究；约20%用于提升在AI及大数据领域的技术能力；约10%用于拓展至 更多地区及海外市场；约10%用作营运资金及其他一般公司用途。 本文源自：金融界AI电报 ...

Core Viewpoint - The China Securities Regulatory Commission has confirmed the overseas listing applications for five companies, all of which are set to list in Hong Kong, with two of them already listed in the US market [1][4]. Group 1: Company Summaries - **Xiaoma Zhixing** plans to issue up to 102,146,500 ordinary shares for listing on the Hong Kong Stock Exchange. The company is headquartered in Guangzhou and specializes in autonomous driving systems for taxis and trucks. As of the first half of 2025, it reported revenues of $35.43 million and a net loss of $96.09 million [1][4][5]. - **Wenyan Zhixing** intends to issue up to 102,428,200 ordinary shares for its Hong Kong listing. The company develops autonomous driving systems and software, holding licenses in seven countries. In the first half of 2025, it reported revenues of $2 billion and a net loss of $7.92 billion [1][6][5]. - **Yujian Xiaomian** aims to issue up to 235,108,000 ordinary shares for its Hong Kong listing. The company operates a chain of Chinese restaurants, primarily offering Chongqing noodles. As of April 5, 2025, it had 374 restaurants in mainland China and 6 in Hong Kong. Revenue figures from 2022 to 2024 were $418 million, $801 million, and $1.154 billion, with corresponding net profits of -$35.97 million, $45.91 million, and $60.70 million [1][8][5]. - **Qingsong Jiankang** plans to issue up to 36,496,400 ordinary shares for its Hong Kong listing. The company provides digital health services and health insurance solutions. Revenue figures from 2022 to 2025 were $394 million, $490 million, $945 million, and $656 million, with net profits of -$9.10 million, $97.17 million, $8.99 million, and $86.05 million [1][10][5]. - **Tudatong** intends to merge with TechStar Acquisition Corporation to achieve a listing on the Hong Kong Stock Exchange, issuing up to 190,240,000 ordinary shares. The company specializes in the development and production of automotive-grade lidar for advanced driving assistance systems and autonomous driving. Revenue figures from 2022 to 2024 were $66.30 million, $121 million, and $160 million, with net losses of $188 million, $219 million, and $398 million [1][11][5].

Group 1 - The China Securities Regulatory Commission has issued a notice regarding QingSong Health Corporation's plan to issue up to 36,496,400 shares for overseas listing on the Hong Kong Stock Exchange [1] - QingSong Health Corporation is a one-stop platform in China focused on providing digital integrated health services and health insurance solutions [3] - According to a report by Sullivan, QingSong Health Corporation ranks 10th in China's digital integrated health services and health insurance market based on projected revenue for 2024 [3] Group 2 - The company ranks 7th in China's digital health services market based on projected revenue for 2024 [3] - QingSong Health Corporation aims to provide accessible, precise, and affordable health solutions to those in need [3]

Core Viewpoint - The company, Qingsong Health Group, has submitted a listing application to the Hong Kong Stock Exchange after a previous application expired, indicating a renewed effort to go public and raise capital for growth initiatives [1]. Group 1: Financial Performance - The company's projected revenues for 2022, 2023, 2024, and the first half of 2025 are approximately CNY 394 million, CNY 490 million, CNY 945 million, and CNY 656 million respectively, showing significant growth potential [1]. - Net profits are expected to fluctuate, with estimates of approximately CNY -9.1 million, CNY 97.2 million, CNY 8.99 million, and CNY 86.1 million for the same periods, indicating volatility in profitability [1]. Group 2: User Base and Services - Qingsong Health focuses on providing digital comprehensive health services and health insurance solutions, catering to users seeking holistic health solutions, including screening, health checks, medical appointments, and health product sales [2]. - The registered user numbers are projected to be around 155 million, 164 million, 168 million, and 168 million for the years 2022 to 2025, while active users are expected to decline from 71 million to 23 million over the same period [2]. Group 3: Revenue Dependence - The company relies heavily on its top five clients, with their revenue contributions being 75.4%, 71.7%, 65.6%, and 65.9% of total revenue from 2022 to the first half of 2025, and the largest client contributing 35.1%, 25.3%, 22.9%, and 25.0% respectively [3]. - The procurement from the top five suppliers accounts for 42.0%, 36.1%, 70.1%, and 77.4% of total procurement during the same periods, indicating a significant reliance on a limited number of suppliers [3]. Group 4: Fundraising Purpose - The funds raised from the IPO will primarily be used to enhance brand awareness, increase user engagement, strengthen partnerships, invest in medical and real-world research, improve AI and big data capabilities, and expand into new regions and overseas markets [2].

Core Viewpoint - Easy Health Group submitted a listing application to the Hong Kong Stock Exchange on August 31, with CICC and China Merchants Securities International as joint sponsors, after its previous application became invalid on August 20 [1]. Group 1: Company Overview - Easy Health Group was established in 2014 and focuses on providing digital integrated health services and health insurance solutions [2]. - The company plans to spin off its online disease fundraising service and transfer all equity of this service and the Duol Hospital to Zhonglang Group, which is seen as a compliance necessity and a way to alleviate potential listing burdens [3]. Group 2: Financial Performance - For the reporting periods from 2022 to 2024, Easy Health Group reported revenues of approximately 394 million RMB, 490 million RMB, 945 million RMB, and 656 million RMB, with profits (losses) of -9.098 million RMB, 9.7169 million RMB, 0.899 million RMB, and 8.6045 million RMB respectively [3][4]. - The revenue contribution from digital integrated insurance services has decreased over the years, accounting for 81.5%, 66.7%, 34%, 41.6%, and 22.9% of total revenue during the reporting periods [4]. Group 3: User Engagement and Marketing - The gross profit margin of Easy Health Group has been declining, recorded at 82.6%, 79.9%, 38.3%, and 32.5% across the reporting periods, while active user numbers have also decreased from 70.5 million to 22.7 million [5]. - The company has incurred high sales and marketing expenses, which were approximately 65.8 million RMB, 124 million RMB, 159 million RMB, 72.4 million RMB, and 103 million RMB, representing 16.7%, 25.3%, 16.8%, 20.4%, and 15.7% of revenue respectively [7]. Group 4: Regulatory Issues - In 2022, Easy Health Group's subsidiary, Guangdong Easy Insurance Brokerage Co., was fined 1 million RMB for misleading advertising practices related to insurance products [7]. - Recent complaints against Easy Insurance have surfaced on the Black Cat Complaint platform, alleging issues such as unauthorized charges and aggressive marketing tactics [8].

Core Viewpoint - Easy Health Group submitted a listing application to the Hong Kong Stock Exchange on August 31, 2023, after its previous application became invalid on August 20, 2023 [1]. Company Overview - Easy Health Group was established in 2014 and focuses on providing digital integrated health services and health insurance solutions [4]. - In June 2024, the group plans to spin off its online disease fundraising service and transfer all equity in this service and its hospital to Zhonglang Group [4]. Financial Performance - The group reported revenues of approximately 394 million RMB, 490 million RMB, 945 million RMB, and 656 million RMB for the years 2022 to 2024 and the first half of 2025, respectively [4]. - The profits (losses) from continuing operations during the same periods were -9.098 million RMB, 9.7169 million RMB, 0.899 million RMB, and 8.6045 million RMB [5]. - The gross profit margin has been declining, recorded at 82.6%, 79.9%, 38.3%, and 32.5% over the reporting periods [6]. User Engagement - Active user numbers have decreased significantly, from 70.5 million to 22.7 million over the reporting periods [6]. - The group acknowledges that its success relies on maintaining and expanding its user base [8]. Marketing and Compliance Issues - The group has incurred high sales and marketing expenses, which were approximately 65.8 million RMB, 124 million RMB, 159 million RMB, 72.4 million RMB, and 103 million RMB, representing 16.7%, 25.3%, 16.8%, 20.4%, and 15.7% of revenue, respectively [8]. - Easy Health Group's subsidiary, Guangdong Easy Insurance Brokerage Co., was fined 1 million RMB in 2022 for misleading marketing practices [8]. - Recent complaints against Easy Insurance have surfaced, alleging issues such as unauthorized charges and aggressive marketing tactics [9].